
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Eccrine sweat glands may play a role in wound healing, and a better understanding of this role may guide the development of improved therapies, researchers report.






